Response

J Natl Cancer Inst. 2015 Mar 3;107(4):djv039. doi: 10.1093/jnci/djv039. Print 2015 Apr.

Authors

Aiko Nagayama¹, Tetsu Hayashida², Hiromitsu Jinno¹, Maiko Takahashi¹, Yuko Kitagawa¹

Affiliations

¹ Department of Surgery, Keio University School of Medicine, Tokyo, Japan (AN, TH, HJ, MT, YK).
² Department of Surgery, Keio University School of Medicine, Tokyo, Japan (AN, TH, HJ, MT, YK). tetsu@z7.keio.jp.

PMID: 25739418
DOI: 10.1093/jnci/djv039

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biomarkers, Tumor / antagonists & inhibitors*
Breast Neoplasms / chemistry*
Breast Neoplasms / drug therapy*
Female
Humans
Neoadjuvant Therapy / methods*
Receptor, ErbB-2 / antagonists & inhibitors*

Substances

Biomarkers, Tumor
Receptor, ErbB-2